Everything below concerns Anti-doping testing. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
To perform a selective separation, the distribution ratio of the solute to be extracted must be greater than one, whereas that belonging to the solutes which remain in the aqueous feed must be lower than one. This always yields a separation factor SF > 1. Generally, the effects of acidity and temperature on distribution ratios and the separation factor are investigated because the main species with actinides and lanthanides could be prone to decomplexation upon increasing acidity due to protonation of the ligand or due to increasing temperature. The thermodynamic effects are usually investigated by performing extraction tests at increasing temperature. Furthermore, thermodynamics studies can assess the several alkyl chains of a ligand on its complexation properties towards minor actinides than lanthanides. The extraction processes are based on the complexation of metal ions with lipophilic or hydrophilic ligands. The extracting agent forms a coordination complex with the metal ion as a product of a Lewis acid-base reaction. Ligands are named bases (donors) and contain at least one electron lone pair to donate to metal ions named acids (acceptors). Metal cations in the aqueous feed raffinate are generally solvated by coordinating water molecules through the donor oxygen atoms to form aquo ions
==== Enzymes ==== Industrial fermentation can be used for enzyme production, where proteins with catalytic activity are produced and secreted by microorganisms. The development of fermentation processes, microbial strain engineering and recombinant gene technologies has enabled the commercialization of a wide range of enzymes. Enzymes are used in all kinds of industrial segments, such as food (lactose removal, cheese flavor), beverage (juice treatment), baking (bread softness, dough conditioning), animal feed, detergents (protein, starch and lipid stain removal), textile, personal care and pulp and paper industries.
However, the results of the 2012 presidential elections gave the PS wins in both districts with a smaller margin in the 7th (Hollande: 51.71% / Sarkozy: 48.29%) than in the 8th (Hollande 64.21% / Sarkozy: 35.79%).
=== Activation by cellular stress === p53 is activated in response to a range of cellular stressors, including DNA damage (for example from ultraviolet or ionizing radiation), osmotic shock, ribonucleotide depletion, oncogene activation, and some viral infections. Activation involves stabilization of the p53 protein, resulting in its accumulation in the nucleus, and regulatory changes that promote sequence-specific DNA binding and transcriptional activation of target genes. These processes are initiated in part by phosphorylation of residues in the N-terminal transactivation domain by stress-activated kinases. Phosphorylation of sites within the Mdm2-binding region (for example Ser20) can reduce binding to MDM2 and thereby decrease ubiquitin-mediated degradation of p53.
Sources: en.wikipedia.org
Tazarotene-induced gene-1 (TIG1) is a protein which has been implicated as a putative tumor suppressor. It is structurally similar to the protein latexin, which has also been shown to demonstrate some tumor suppression activity (Liang et al., 2007). TIG1 is thought to be a transmembrane protein, and its mechanism of tumor suppression is largely unknown.
. In chromatography, the area of a peak is proportional to the number of moles (n) times some constant of proportionality (k), Area = k×n. The number of moles of compound is equal to the concentration (c) times the volume, n = cV. From these equations, the following derivation is made:
==== Lucid dreaming ==== Lucid dreaming has been found to be associated with greater mental well-being. It also was not associated with poorer sleep quality nor with cognitive dissociation. There is also some evidence lucid dreaming therapy can help with nightmare reduction.
Sources: en.wikipedia.org
=== Magnetic substrates === In 2010, researchers magnetized graphene by producing it via CVD on the Ni(111) substrate and then in 2014 by placing it on an atomically smooth layer of magnetic yttrium iron garnet, maintaining graphene's electronic properties unaffected. Previous methods involved doping graphene with other substances. The dopant's presence negatively affected its electronic properties.
In a meta-analysis of 20 studies involving 1,466 patients with coronary artery disease, CRP levels were found to be reduced after exercise interventions. Among those studies, higher CRP concentrations or poorer lipid profiles before beginning exercise were associated with greater reductions in CRP. To clarify whether CRP is a bystander or active participant in atherogenesis, a 2008 study compared people with various genetic CRP variants. Those with a high CRP due to genetic variation had no increased risk of cardiovascular disease compared to those with a normal or low CRP. A study published in 2011 shows that CRP is associated with lipid responses to low-fat and high-polyunsaturated fat diets.
Ulrich Hersel; Claudia Dahmen; Horst Kessler (2003). "RGD modified polymers: biomaterials for stimulated cell adhesion and beyond". Biomaterials. 24 (24): 4385–4415. doi:10.1016/s0142-9612(03)00343-0. PMID 12922151. Wikidata Q34223126. Marco Arnold; Elisabetta A Cavalcanti-Adam; Roman Glass; Jacques Blümmel; Wolfgang Eck; Martin Kantlehner; Horst Kessler; Joachim P Spatz (2004). "Activation of integrin function by nanopatterned adhesive interfaces". ChemPhysChem. 5 (3): 383–388. doi:10.1002/cphc.200301014. PMID 15067875. Wikidata Q44832858. Kessler, Horst (July 1982). "Conformation and Biological Activity of Cyclic Peptides". Angewandte Chemie International Edition in English. 21 (7): 512–523. doi:10.1002/anie.198205121. ISSN 0570-0833. Dechantsreiter MA; Planker E; Mathä B; Lohof E; Hölzemann G; Jonczyk A; Goodman SL; Kessler H (1999). "N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists". Journal of Medicinal Chemistry. 42 (16): 3033–3040. doi:10.1021/jm970832g. PMID 10447947. Wikidata Q30580638. Elisabetta A Cavalcanti-Adam; Tova Volberg; Alexandre Micoulet; Horst Kessler; Benjamin Geiger; Joachim Pius Spatz (2007). "Cell spreading and focal adhesion dynamics are regulated by spacing of integrin ligands". Biophysical Journal. 92 (8): 2964–2974. doi:10.1529/biophysj.106.089730. PMC 1831685. PMID 17277192. Wikidata Q30479140. Kessler, Horst (2023). NMR: Mein Kompass in der Organischen und Medizinischen Chemie [NMR: my compass in organic and medicinal chemistry]. Berlin: GNT Publishing GmbH. ISBN 978-3-86225-132-2.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.